Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Royalty Pharma plc shares valued at $815,634 were sold by Urist Marshall on Jan 09 ’26. At $40.78 per share, Urist Marshall sold 20,000 shares. The insider’s holdings dropped to 60,000 shares worth approximately $2.38 million following the completion of this transaction.
Also, George Lloyd purchased 495,860 shares, netting a total of over 20,523,645 in proceeds.
Before that, Coyne Terrance P. had sold 69,582 shares from its account. In a trade valued at $2,673,041, the EVP & CFO traded Royalty Pharma plc shares for $38.42 each. Upon closing the transaction, the insider’s holdings decreased to 69,582 shares, worth approximately $1.58 million.
As published in their initiating research note from Goldman on September 30, 2025, Royalty Pharma plc [RPRX] has been a Buy and the price target has been revised to $42. Analysts at Morgan Stanley started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid May. As of June 03, 2024, UBS has decreased its “Buy” rating to a “Neutral” for RPRX.
Analyzing RPRX Stock Performance
On last trading session, Royalty Pharma plc [NASDAQ: RPRX] plunged -1.22% to $39.72. The stock’s lowest price that day was $39.6, but it reached a high of $40.335 in the same session. During the last five days, there has been a drop of approximately -1.34%. Over the course of the year, Royalty Pharma plc shares have jumped approximately 32.27%.
Support And Resistance Levels for Royalty Pharma plc (RPRX)
RSI (Relative Strength Index) is 51.97 on the 14-day chart, showing neutral technical sentiment.
Is Royalty Pharma plc subject to short interest?
Stocks of Royalty Pharma plc saw a sharp rise in short interest on 2025-12-31 jumping by 4.47 million shares to 28.8 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 24.33 million shares. A jump of 15.52% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.97 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.97.
Which companies own the most shares of Royalty Pharma plc (RPRX)?
In terms of Royalty Pharma plc share price expectations, FactSet research, analysts set an average price target of 43.5 in the next 12 months, up nearly 8.18% from the previous closing price of $40.21. Analysts anticipate Royalty Pharma plc stock to reach 45 by 2026, with the lowest price target being 42. In spite of this, 6 analysts ranked Royalty Pharma plc stock as Buy at the end of 2026. On May 13, 2022, Scotiabank assigned a price target of “a Sector outperform” to the stock and initiated coverage with a $53.
